Status:
COMPLETED
Modulation of Remifentanil-induced Postinfusion Hyperalgesia
Lead Sponsor:
Ullevaal University Hospital
Collaborating Sponsors:
University of Oslo
Rikshospitalet University Hospital
Conditions:
Hyperalgesia, Secondary
Eligibility:
MALE
18-70 years
Phase:
PHASE4
Brief Summary
In addition to alleviate pain there is growing evidence that µ-opioids enhance pain. This problem is known as opioid induced hyperalgesia(OIH).The NMDA receptor is involved in opioid induced hyperalge...
Detailed Description
Remifentanil is an fast acting opioid which has become very popular to use during surgery. There are studies, both experimental 1-3 and clinical 4;5, which indicate that remifentanil after end of inf...
Eligibility Criteria
Inclusion
- Healthy volunteers
Exclusion
- Allergy to the drugs used in the study
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00785863
Start Date
December 1 2008
End Date
April 1 2009
Last Update
July 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ullevaal University Hospital
Oslo, Oslo County, Norway, 0407